Introduction
============

Bone and soft tissue sarcomas (BSTS) are connective tissue malignancies arising from tissues of mesenchymal origin ([@b1-mco-0-0-1994]). BSTS may occur in all age groups. However, it is not common in adolescents and young adults (AYAs) aged 15-39 years ([@b2-mco-0-0-1994]) with these tumors comprising only 6-8% of all malignancies in AYAs ([@b3-mco-0-0-1994]). The mortality rates among AYAs with BSTS are high as these types of cancer confer poorer prognoses than those of other types such as Hodgkin\'s lymphoma, melanoma, or germ cell tumors ([@b6-mco-0-0-1994]). In AYA sarcomas also confer poorer prognoses than in both, younger and older patients, irrespective of the histological type ([@b6-mco-0-0-1994]). However, data from clinical investigations of the outcomes of AYA patients with BSTS are scarce ([@b2-mco-0-0-1994],[@b7-mco-0-0-1994]).

In this study, we aimed to determine the survival rates of AYAs with BSTS at the Kindai University Hospital and the factors contributing to poorer prognosis in patients of this age group.

Patients and methods
====================

### Patients

The records of 7 male patients and 6 female patients aged 17-39 (mean: 34 years) with BSTS were reviewed retrospectively between October 2009 and July 2017. Data on the size, histological grade, location, stage, treatment modalities, local recurrence, presence of metastasis, and final outcomes were recorded. The resected specimens were stained with hematoxylin-eosin (H&E). The histological grade was determined based on the four-point grading system for bone tumors ([@b11-mco-0-0-1994]) and the Federation Nationale des Centres de Lutte Contres le Cancer grading system for soft tissue tumors ([@b12-mco-0-0-1994]).

This study was approved by the Ethics Committee of Kindai University Hospital (approval no.: 31-153) (Osaka, Japan). All patients also provided written informed consent for the participation of this retrospective study.

### Methods

The grading system for bone tumors, with the exception of Ewing sarcoma, was based on a previously described system ([@b11-mco-0-0-1994]). Tumors of grades 1-2 and 3-4 were considered as low- and high-grades, respectively. Among soft tissue tumors, lesions of grades 1 and 2-3 were classified as low- and high-grade, respectively. The clinical staging was individually evaluated based on the American Joint Committee on Cancer (AJCC) 7th edition for soft tissue tumors and bone cancer ([@b13-mco-0-0-1994],[@b14-mco-0-0-1994]). The mean follow-up period was 45 (range: 11-111 months). Surgery was aimed at achieving wide surgical margins in all cases ([Table I](#tI-mco-0-0-1994){ref-type="table"}: 11/13 cases). The surgical margins in resected specimens were categorized as R0, R1, or R2, as previously classified ([@b15-mco-0-0-1994]). The patients\' 5-year survival rates were calculated using the Kaplan-Meier method; and the 5-year survival rates of younger (15-29 years) and older (≥30) patients, as well as that of patients with bone vs. soft tissue sarcoma, low-vs. high-grade tumors, and trunk-vs. extremity-located tumors using log-rank tests.

### Statistical analysis

The Statmate 4.01 software package was used to assess the 5-year survival rates. The patients\' 5-year survival rates were calculated using the Kaplan-Meier method and differences were assessed using the log-rank test. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Patients and treatment

Seven and six patients had bone and soft tissue sarcomas, respectively. Among those with bone sarcomas, four, two, and one had osteosarcoma, chondrosarcoma, and Ewing sarcoma, respectively; three had high-grade disease, while the tumors were of low grades in the remainder. Among the six patients with soft tissue sarcomas, three had myxoid liposarcoma, two had synovial sarcoma, and one had Ewing sarcoma; six and one had high- and low-grade disease, respectively ([Table I](#tI-mco-0-0-1994){ref-type="table"}). Nine sarcomas were located in the lower limbs, three were in the trunk, and one was in the upper limbs. Sarcomas in older patients were staged according to the AJCC criteria: Stage I (n=3), IIA (n=1), II (n=3), III (n=4), IV (n=1), and IVB (n=1). Lymph node metastases were observed during the first examination in 1 case ([Table I](#tI-mco-0-0-1994){ref-type="table"}; patient number 2). In addition, lung metastasis had developed in 3 cases during treatment ([Table I](#tI-mco-0-0-1994){ref-type="table"}; patient numbers 4, 6, and 13). A total of 11 patients underwent tumor resections (wide and marginal in 9 and 2, respectively). The surgical margin status was R0, R1, and R2 in 7, 3, and 1 cases, respectively ([Table I](#tI-mco-0-0-1994){ref-type="table"}). The remaining two patients did not undergo surgery owing to difficulties in accessing the pelvic tumor and extensive disease in 1 case each; these patients were treated with 5-6 courses of chemotherapy according to the NECO-95J protocol ([@b16-mco-0-0-1994]) and heavy-particle radiotherapy (70 Gy) (n=2). Chemotherapy was selected for soft tissue sarcomas that were exceptionally large or in close proximity to vessels or nerves, precluding the achievement of wide margins; chemotherapy was also administered in cases where the margin was positive after surgery. We administered ifosfamide and doxorubicin hydrochloride to all patients with myxoid liposarcoma, synovial sarcoma, and leiomyosarcoma ([@b17-mco-0-0-1994]). We also administered vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide to patients with Ewing sarcoma ([@b18-mco-0-0-1994]). In cases of bone sarcoma, chemotherapy was administered to patients with osteosarcoma according to the NECO-95J protocol using the same dosage as that used for adults ([@b16-mco-0-0-1994]). No lethal side-effects were noted in any of the patients ([Table II](#tII-mco-0-0-1994){ref-type="table"}).

### Recurrence

Two patients experienced local recurrence. No evidence of disease (NED) status was maintained in 1 case after a second resection of the osteosarcoma in the tibia 36 months after the first marginal resection. This patient had undergone marginal resection after being misdiagnosed with a giant cell tumor on histological evaluation of the biopsy sample. The other patient had a myxoid liposarcoma of the thigh that recurred 73 months after wide- resection; this patient also achieved NED status after undergoing a second resection. Images from her first MRI showed a myxomatous tumor ([Fig. 1A](#f1-mco-0-0-1994){ref-type="fig"} and [B](#f1-mco-0-0-1994){ref-type="fig"}). This was resected widely, and the histology was found to be myxoid liposarcoma ([Fig. 1C](#f1-mco-0-0-1994){ref-type="fig"}). The surgical margins were inadequate (R1), and a recurrence occurred in the nerve, 6 years after the surgery ([Fig. 2A](#f2-mco-0-0-1994){ref-type="fig"} and [B](#f2-mco-0-0-1994){ref-type="fig"}) leading to the tumor being removed marginally. The histology revealed recurrent liposarcoma ([Fig. 2C](#f2-mco-0-0-1994){ref-type="fig"}).

The clinical results indicated a CDF, NED, and dead of disease (DOD) status in 6, 2, and 5 cases, respectively. The inadequate margins (R1 or R2) in 4 cases led to recurrence and DOD status in 2 and 1 cases, respectively.

### Survival

The 5-year survival rate for the entire cohort was 57.1% ([Fig. 3A](#f3-mco-0-0-1994){ref-type="fig"}). The survival rate of younger patients (15-29 years) was lower than that of their older counterparts (≥30 years) (37.5 vs. 63.4%, P=0.43, [Fig. 3B](#f3-mco-0-0-1994){ref-type="fig"}). The differences in survival were similar between patients with bone and soft tissue tumors (72.0 vs. 64.2%, P=0.53, [Fig. 3C](#f3-mco-0-0-1994){ref-type="fig"}). The 5-year survival rate was decreased in patients with high-grade compared to low-grade sarcomas (32.4 vs. 100%, P\<0.001, [Fig. 3D](#f3-mco-0-0-1994){ref-type="fig"}). The 5-year survival rate was also decreased in patients with sarcomas located in the trunk compared to in the extremities (0 vs. 76.2%, P=0.017, [Fig. 3E](#f3-mco-0-0-1994){ref-type="fig"}).

Discussion
==========

The clinical outcomes in AYAs with BSTS have not improved owing to the lack of actionable data ([@b10-mco-0-0-1994]). In the present study, we determined the clinical features and outcomes of AYA patients with BSTS.

Three of the major histological types of malignant bone sarcomas among AYAs (based on incidence rates) are osteosarcomas, Ewing sarcomas of the bone, and chondrosarcoma ([@b19-mco-0-0-1994]). The major histological types of soft tissue sarcomas found in AYAs include rhabdomyosarcomas, synovial sarcomas, leiomyosarcomas, undifferentiated pleomorphic sarcomas, and liposarcomas ([@b5-mco-0-0-1994],[@b19-mco-0-0-1994]). In the present study, almost all AYAs with BSTS had one of the major histological types; however, Ewing sarcoma of the bone, which was found in one patient, is relatively rare in the AYA age group.

Major sarcomas may metastasize to lymph nodes more frequently in AYAs than in younger and older age groups ([@b20-mco-0-0-1994],[@b21-mco-0-0-1994]); lymph node metastatic status was previously found to be the most important prognostic factor in patients with sarcomas ([@b22-mco-0-0-1994],[@b23-mco-0-0-1994]). In the present study, only one patient experienced sequential metastases to the lymph nodes and lung, and subsequently succumbed to the disease.

In general, surgical margins are associated with the prognosis of malignant bone and soft tissue tumors ([@b24-mco-0-0-1994],[@b25-mco-0-0-1994]). Previous findings demonstrated that the surgical margin is associated with the prognosis of malignant bone and soft tissue tumors in AYA patients ([@b26-mco-0-0-1994]). In the present study, inadequate surgical margins conferred poor prognosis.

Previous findings have shown that 5-year survival rates for AYA patients with BSTS range from 68.7 to 75.3% ([@b10-mco-0-0-1994],[@b27-mco-0-0-1994]). Being in the AYA age group is an independent negative prognostic factor for patients with cancer ([@b28-mco-0-0-1994]). In addition, survival rates in AYA patients with osteosarcoma were significantly poorer than those of children ([@b7-mco-0-0-1994],[@b29-mco-0-0-1994]). By contrast, in another study it was shown that being in the AYA age group does not influence the prognosis of patients with bone sarcoma ([@b10-mco-0-0-1994]). In the present study, the 5-year survival rate was poorer than both the rates reported in previous studies, and that of older patients with sarcoma (86.02%) included in the present study ([@b30-mco-0-0-1994]). These data support the hypothesis that being in the AYA age group is a poor prognostic factor.

The prognostic factors for sarcoma in AYA patients have been previously explored ([@b5-mco-0-0-1994],[@b10-mco-0-0-1994],[@b31-mco-0-0-1994]). Previous findings have shown that older age, large tumor size, high grade, lack of neoadjuvant chemotherapy, and positive surgical margin adversely influence prognosis ([@b32-mco-0-0-1994]). In the present study, younger patients with sarcomas had poorer 5-year survival rates than that of the older patients. Patients with sarcomas of the trunk had poorer 5-year survival rates than those with sarcomas in the extremities. Patients with high-grade sarcomas also had poorer 5-year survival rates than those with low-grade tumors. Thus, younger age, trunk location, and high-grade status appear to be poor prognostic factors in AYA patients with BSTS.

Our study had certain limitations. First, the number of patients was small. Consequently, statistical analysis was not feasible, and the report was therefore descriptive. Second, the included tumors were considerably diverse. Third, we were unable to compare the outcomes of these patients to those of younger patients with sarcoma, and a future comparative study has been planned.

In conclusion, in the present study, we determined the clinical features and outcomes of AYA patients with BSTS. Younger age, trunk location, and high-grade tumors were associated with poorer 5-year survival rates. Therefore, BSTS located in the trunk or of high-grade should be treated more aggressively in younger AYA patients.
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![(A) Coronal T1-weighed MRI image of the thigh. The tumor intensity is low. (B) Transverse slices of T2-weighed MRI images of the thigh. The tumor intensity is high. (C) Histological findings on hematoxylin-eosin (H&E) staining. Small atypical cells proliferating in the background of a mucus matrix. Some lipoblasts are also noted. Red arrows indicate the tumor mass. Scale bar, 100 µm.](mco-12-04-0358-g00){#f1-mco-0-0-1994}

![(A) Coronal T1-weighed MRI image of the thigh. The recurrence tumor intensity is low. (B) Transverse slices of T2-weighed MRI images of the thigh. The intensity of the recurrent tumor is high. (C) Histological findings on staining with hematoxylin-eosin (H&E). Small or star-shaped atypical cells are found in the mucus matrix. Poorly differentiated proliferating lipoblasts with fat vacuoles are also noted. Red arrows indicate the tumor mass. Scale bar, 100 µm.](mco-12-04-0358-g01){#f2-mco-0-0-1994}

![Kaplan-Meier curves showing survival rates in various groups. (A) Survival rates in adolescents and young adults with sarcoma according to age. (B) Survival rates in patients with sarcoma who were 15-29 years (red line) vs. those who were 30 years of age and older (blue line). Survival was poorer in patients with sarcomas of 15-29 years of age. There was no significant difference between these age groups (P=0.43). (C) Survival rates in adolescents and young adults with soft tissue sarcomas (red line) vs. bone sarcoma (blue line). Survival rates were similar in patients of both groups. There was no significant difference according to sarcoma type (P=0.53). (D) Survival rates of adolescents and young adults with high-grade (red line) vs. low-grade sarcoma (blue line). Survival was significantly poorer in the high-grade sarcoma group (P\<0.001). (E) Survival rates in adolescents and young adults with sarcomas of the trunk (red line) vs. extremities (blue line). Survival was significantly poorer in patients with sarcomas of the trunk (P=0.017).](mco-12-04-0358-g02){#f3-mco-0-0-1994}

###### 

Clinical features of patients with sarcoma.

  Patient no.   Age (y)/Sex   Size (mm)   Bone or soft tissue   Site           Histopathology       Grade   Stage   Treatment   Surgical margin   Local recurrence   Metastasis   Follow-up (Mo)   Outcome
  ------------- ------------- ----------- --------------------- -------------- -------------------- ------- ------- ----------- ----------------- ------------------ ------------ ---------------- ---------
  1             27/F          85x36       B                     Sacrum         Osteosarcoma         High    III     CT, HPR     \-                \-                 \-           11               DOD
  2             32/M          120x60      S                     Buttock        Ewing sarcoma        High    IV      WR, CT      R0                \-                 \+           13               DOD
  3             35/M          21x8        S                     Knee           Synovial sarcoma     High    II      WR          R1                \-                 \-           20               CDF
  4             34/M          94x62       B                     Pelvic         Ewing sarcoma        High    III     CT, HPR     \-                \-                 \+           24               DOD
  5             27/F          45x36       S                     Side abdomen   Synovial sarcoma     High    I       CT, WR      R0                \-                 \-           36               CDF
  6             17/M          107x67      B                     Pelvic         Osteosarcoma         High    IVB     CT, WR      R1                \+                 \+           43               DOD
  7             35/F          105x59      S                     Thigh          Leiomyosarcoma       High    II      CT, WR      R0                \-                              45               DOD
  8             36/F          73x65       B                     Tibia          Osteosarcoma         Low     IIA     CT, MR      R2                \+                 \-           54               NED
  9             36/F          13x13       S                     Upper arm      Myxoid Liposarcoma   Low     II      WR          R0                \-                 \-           54               CDF
  10            39/M          120x24      B                     Thigh          Chondrosarcoma       Low     I       WR          R0                \-                 \-           63               CDF
  11            26/F          143x39      S                     Thigh          Myxoid Liposarcoma   High    III     WR          R0                \-                 \-           66               CDF
  12            33/M          44x21       B                     Femur          Chondrosarcoma       Low     I       MR          R0                \-                 \-           72               CDF
  13            34/F          162x99      S                     Thigh          Myxoid Liposarcoma   High    III     CT, WR      R1                \+                 \+           111              NED

y, years; F, female; M, male; B, bone; S, soft tissue; CT, chemotherapy; HPR, heavy particle radiation; WR, wide resection; MR, marginal resection; Mo, Month(s); DOD, dead of disease; CDF, continuously disease-free.

###### 

Chemotherapy toxic effects, worst grade per patient.

  Item                     Grade 0   Grade 1   Grade 2   Grade 3   Grade 4
  ------------------------ --------- --------- --------- --------- ---------
  Hematological                                                     
       White blood cells   3         2         2         1         0
       Neutrophils         2         1         3         2         0
       Platelets           5         2         1         0         0
  Biochemical                                                       
       Creatinine          0         0         0         0         0
       AST                 6         1         1         0         0
       ALT                 6         1         1         0         0
  Clinical                                                          
       Nausea              2         2         2         0         0
       Vomiting            1         0         0         0         0
       Diarrhoea           1         0         0         0         0
       Mucositis           0         0         0         0         0
       Alopecia            1         3         1         0         0
       Fever               2         0         0         0         0
       Infection           0         0         0         1         0
       Neurological        0         0         0         0         0
       Cardiac             0         0         0         0         0

Toxic effects were assessed using the National Cancer Institute common toxicity criteria (version 1). Data are number of patients (%). Laboratory data available for 8 patients, clinical data for 6 patients. AST, aspartate aminotransferase; ALT, alanine aminotransferase.
